Protego Biopharma Secures $130M Series B Funding

Why It Matters

The infusion of $130 million extends Protego’s runway, enabling accelerated progression of its immuno‑oncology programs toward commercialization. It also signals growing pharma interest in novel antibody platforms, potentially reshaping competitive dynamics in biotech.

Key Takeaways

• $130M Series B led by Novartis Venture Fund
• New investors include Omega Funds, Droia Ventures, YK Bioventures
• Funding targets clinical development of Protego’s pipeline
• Existing backers reaffirm confidence in company’s platform
• Capital extends runway through late-stage trials

Pulse Analysis

The biotech financing landscape in 2025 continues to favor companies with differentiated platforms, and Protego Biopharma’s $130 million Series B is a textbook example. Led by the Novartis Venture Fund and Forbion, the round attracted a mix of strategic and financial investors, including Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures. Such a coalition reflects both confidence in Protego’s scientific approach and a broader appetite for immuno‑oncology assets that can address unmet cancer indications. The capital influx also aligns with a surge of late‑stage funding for companies nearing pivotal trial milestones.

Protego’s core asset is a proprietary antibody platform designed to modulate the tumor micro‑environment and enhance immune checkpoint efficacy. The company currently advances three candidates—two bispecific antibodies and one antibody‑drug conjugate—through Phase 1/2 studies in solid tumors. The new financing will fund the transition of these programs into Phase 2b/3 trials, accelerate manufacturing scale‑up, and support regulatory engagements across the United States, Europe, and Asia. If successful, Protego could capture a sizable share of the $150 billion global oncology market, especially in indications where current therapies show limited durability.

From an industry perspective, the round underscores a shifting investment paradigm where large pharma venture arms, such as Novartis, increasingly co‑lead rounds to secure early access to innovative modalities. This partnership model reduces risk for both parties and speeds the path to market. Moreover, the involvement of European and Asian venture firms signals a truly global interest in Protego’s technology, potentially easing future cross‑border collaborations and licensing deals. As the pipeline matures, the company is poised to become a strategic acquisition target or a partner for larger pharmaceutical entities seeking to bolster their oncology portfolios.

Deal Summary

Protego Biopharma, a clinical-stage biotech based in San Diego, closed a $130 million Series B round led by Novartis Venture Fund and Forbion, with participation from several new and existing investors.